Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy-Reference-Cited by-同舟云学术

Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy

Published:2023-06-01 Issue:3 Volume:33 Page:193-208
ISSN:2159-3337
Container-title:Nucleic Acid Therapeutics
language:en
Short-container-title:Nucleic Acid Therapeutics

Author:

van Deutekom Judith¹,Beekman Chantal¹,Bijl Suzanne¹,Bosgra Sieto¹,van den Eijnde Rani¹,Franken Dennis¹,Groenendaal Bas¹,Harquouli Bouchra¹,Janson Anneke¹,Koevoets Paul¹,Mulder Melissa¹,Muilwijk Daan¹,Peterburgska Galyna¹,Querido Bianca¹,Testerink Janwillem¹,Verheul Ruurd¹,de Visser Peter¹,Weij Rudie¹,Aartsma-Rus Annemieke²^ORCID,Puoliväli Jukka³,Bragge Timo³,O'Neill Charles⁴,Datson Nicole A.¹

Affiliation:

1. VICO Therapeutics B.V., formerly BioMarin Nederland B.V., Leiden, The Netherlands.

2. Department of Human Genetics, Leiden University Medical Centre, Leiden, The Netherlands.

3. Charles River Discovery Services, Kuopio, Finland.

4. BioMarin Pharmaceutical, Inc., San Rafael, California, USA.

Publisher

Mary Ann Liebert Inc

Subject

Drug Discovery,Genetics,Molecular Biology,Molecular Medicine,Biochemistry

Link

https://www.liebertpub.com/doi/pdf/10.1089/nat.2022.0063

Reference56 articles.